CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Eligibility Criteria

• 1. Diagnosis of carcinoma of the colon or rectum (patients with lymphomatous, sarcomatous, or neuroendocrine features are not eligible).
• 2. Post complete surgical resection of CRC, with last surgery occurring within 180 days prior to enrollment are eligible if all of the following conditions are met:
• 1. in the opinion of the surgeon, all grossly visible tumor was completely resected ("curative resection") and
• 2. histologic evaluation by the pathologist confirms the margins of the resected specimens are not involved by malignant cells.
• 3. Pathologic stage II or III
• 4. ECOG performance status ≤ 2 (0, 1 or 2).
• 5. Able to understand and provide written informed consent.
• 6. Willing and able to comply with the study requirements, which includes the collection of approximately 43mL of blood for each research blood draw.
• 1. Initiated adjuvant therapy for current CRC diagnosis (note: prior neoadjuvant therapy acceptable).
• 2. Pregnant or breastfeeding at time of enrollment.
• 3. Prior history of any invasive cancer (including CRC) within the past 3 years prior to informed consent, with the exception of non-melanoma skin cancer. Patients with a prior history of noninvasive (in situ) carcinomas may participate after definitive treatment.
• 4. Prior transplant history:
• 1. Prior allogeneic hematopoietic stem cell transplant at any time.
• 2. Prior solid organ transplant within the last 2 years prior to enrollment.
• 5. Multiple cancer diagnoses: Synchronous or asynchronous diagnoses (or suspicion) of multiple primary cancers at the time of eligibility screening.